Skip to main content

Table 3 Patient characteristics in the group older than 80 years

From: Early initiation of tolvaptan is associated with early discharge in patients with heart failure regardless of age

 

Early use of TLV

Delayed use of TLV

P value

(n = 40)

(n = 61)

Body mass index (kg/m2)

19.4 ± 2.9

19.7 ± 4.2

0.603

NYHA class (II/III/IV)

0/55/6

1/33/6

0.705

CS class (I/II/III)

19/38/4

6/28/6

0.026

Systolic BP (mm Hg) on admission

130.8 ± 22.7

121.5 ± 19.9

0.037

Diastolic BP (mm Hg) on admission

70.3 ± 13.8

64.1 ± 11.5

0.020

Heart rate (bpm)

82.5 ± 20.5

85.5 ± 23.7

0.506

AST (IU/L)

34.0 ± 22.8

40.9 ± 47.0

0.329

ALT (IU/L)

24.1 ± 18.2

31.5 ± 53.4

0.323

eGFR (ml/min/1.73 m2)

43.8 ± 19.4

40.5 ± 22.8

0.431

Hemoglobin (g/dL)

11.4 ± 1.9

11.0 ± 2.1

0.326

Brain natriuretic peptide (pg/mL)

1502.2 ± 211.9

850.2 ± 96.8

0.019

Ejection fraction (%)

51.0 ± 18.1

55.1 ± 18.5

0.268

HFpEF (n, %)

30, 49.2

23, 57.5

0.418

Length of hospital stay

21.3 ± 12.5

32.9 ± 17.9

 < 0.001

Time until commencement of TLV from hospitalization

3.0 ± 1.3

13.6 ± 11.6

 < 0.001

Length of hospital stay after initiation of TLV

18.3 ± 12.4

19.3 ± 12.7

0.699

  1. NYHA: New York Heart Association, CS: clinical scenario, BP: blood pressure, AST: aspartate aminotransferase, ALT: alanine aminotransferase, eGFR: estimated glomerular filtration rate, HFpEF: heart failure preserved ejection fraction, TLV: tolvaptan. Continuous data are expressed as the mean ± standard deviation or error. P-values were determined using the unpaired t-test